These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3185294)

  • 1. Clinical and hormonal effects of long-term veralipride treatment in post-menopausal women.
    Verbeke K; Dhont M; Vandekerckhove D
    Maturitas; 1988 Oct; 10(3):225-30. PubMed ID: 3185294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Veralipride and menopause].
    Laffargue F; Viala JL; Durand G
    Sem Hop; 1983 Sep; 59(29-30):2127-30. PubMed ID: 6312585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women.
    Melis GB; Gambacciani M; Cagnacci A; Paoletti AM; Mais V; Fioretti P
    Obstet Gynecol; 1988 Nov; 72(5):688-92. PubMed ID: 3140150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Veralipride in the treatment of hot flushes in the menopause].
    Pasetto N; Piccione E; Baschieri L
    Rev Fr Gynecol Obstet; 1985 Feb; 80(3):163-5. PubMed ID: 3922035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of veralipride on LH, FSH, and PRL levels and on the climacteric syndrome].
    De Cecco L; Venturini PL; Alibrandi MP; Grondona AL; Morano S; Penna L; Campanella G; Ragni N
    Rev Fr Gynecol Obstet; 1985 Feb; 80(3):152-5. PubMed ID: 3922034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vaginal smear cytology and hormonal tests before and after treatment with veralipride. Results in eleven cases (author's transl)].
    Sadrin R; Evrard G; Adnet JJ; Wahl P; Quereux C
    Sem Hop; 1980 Oct; 56(37-38):1460-4. PubMed ID: 6254161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Veralipride: alternative antidopaminergic treatment for menopausal symptoms.
    David A; Don R; Tajchner G; Weissglas L
    Am J Obstet Gynecol; 1988 May; 158(5):1107-15. PubMed ID: 2967034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Actual status of veralipride use.
    Carranza-Lira S
    Clin Interv Aging; 2010 Sep; 5():271-6. PubMed ID: 20852674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of luteinizing hormone response to naloxone in postmenopausal women by chronic administration of the antidopaminergic drug veralipride.
    Melis GB; Cagnacci A; Gambacciani M; Paoletti AM; Moggi L; Fioretti P
    J Clin Endocrinol Metab; 1988 May; 66(5):964-7. PubMed ID: 2834413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tolerance to veralipride administered for an extended time].
    Milliez J
    Rev Fr Gynecol Obstet; 1984 Jan; 79(1):27-8, 31. PubMed ID: 6531585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the antidopaminergic drug veralipride on LH and PRL secretion in postmenopausal women.
    Fioretti P; Cagnacci A; Paoletti AM; Gambacciani M; Soldani R; Mauro GA; Spinetti A; Melis GB
    J Endocrinol Invest; 1989 May; 12(5):295-301. PubMed ID: 2549113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Extrapyramidal adverse effects of veralipride (Agreal), a drug used to treat hot flushes: a propos of 17 cases].
    Masmoudi K; Gras-Champel V; Lemaire-Hurtel AS; Masson H; Munier A; Geslin JM; Andréjak M
    Rev Med Interne; 2005 Jun; 26(6):453-7. PubMed ID: 15936474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and clinical and biological tolerance of long-term veralipride administration. Apropos of 74 case reports].
    Dargent D; Dumont M; Malinas Y
    Rev Fr Gynecol Obstet; 1985 Feb; 80(3):171-3. PubMed ID: 3992114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment.
    Vercellini P; Vendola N; Colombo A; Passadore C; Trespidi L; Crosignani PG
    Gynecol Obstet Invest; 1992; 34(2):102-4. PubMed ID: 1398260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study of the action of a new molecule, veralipride, on menopausal psychofunctional disorders (author's transl)].
    Delanian L
    Sem Hop; 1980 Oct; 56(37-38):1468-70. PubMed ID: 6254163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Non-hormonal therapy for menopausal disorders: results of a multicentric double-blind trial (author's transl)].
    Linquette M; Rivière J; Vague J
    Sem Hop; 1980 Oct; 56(37-38):1445-8. PubMed ID: 6254159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Veralipride-induced tardive dystonia in a patient with bipolar psychosis.
    Gabellini AS; Pezzoli A; De Massis P; Sacquegna T
    Ital J Neurol Sci; 1992 Oct; 13(7):621-3. PubMed ID: 1428799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The alternative to hormonal treatment of menopausal vasomotor flushes: veralipride].
    Wesel S; Bosuma WB
    Sem Hop; 1983 Mar; 59(9):596-9. PubMed ID: 6304907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Parkinson syndrome induced by veralipride].
    Franchignoni FP; Tesio L
    Minerva Ginecol; 1995 Jun; 47(6):277-9. PubMed ID: 7478098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety of veralipride.
    De Leo V; Morgante G; Musacchio MC; Faldini E; Delia A; Petraglia F
    Expert Opin Drug Saf; 2006 Sep; 5(5):695-701. PubMed ID: 16907659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.